Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases
Amparo Wolf(Western University), Douglas Kondziolka(Neurological Surgery), Sayyad Yaseen Zia(NYU Langone Health), Anna C. Pavlick(Cornell University), Joshua S. Silverman(NYU Langone Health), Rashika Verma(NYU Langone Health), Melissa Wilson(Massachusetts Institute of Technology), John G. Golfinos(NYU Langone Health)
Cited by 56
Related Papers
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Role of experience and oscillations in transforming a rate code into a temporal code
|Nature|2002|657
The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline
|Journal of Neuro-Oncology|2009|514
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma
|Journal of Clinical Oncology|2021|431